Cargando…

A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC

Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiang, Zeng, Jian, Li, Huanyu, Li, Feng, Jiang, Bin, Zhao, Ming, Liu, Zhuo, Li, Ruineng, Ma, Tiexiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/
https://www.ncbi.nlm.nih.gov/pubmed/35799605
http://dx.doi.org/10.1155/2022/7257738
_version_ 1784741105723506688
author Liu, Xiang
Zeng, Jian
Li, Huanyu
Li, Feng
Jiang, Bin
Zhao, Ming
Liu, Zhuo
Li, Ruineng
Ma, Tiexiang
author_facet Liu, Xiang
Zeng, Jian
Li, Huanyu
Li, Feng
Jiang, Bin
Zhao, Ming
Liu, Zhuo
Li, Ruineng
Ma, Tiexiang
author_sort Liu, Xiang
collection PubMed
description Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders to sorafenib were investigated using the HCC GSE109211 data set. Biological functions and mechanisms were studied using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. The expression levels of differential expressed target genes were identified in HCC tissues, using The Cancer Genome Atlas database, and their prognostic and diagnostic values were explored using survival and receiver operating characteristic curve analysis. A nomogram and risk model of sorafenib-response target genes enabled the evaluation of the prognosis of patients with HCC. The relationship between risk scores and levels of infiltrating immune cells was visualized via correlation analysis. We identified 1620 sorafenib-response target genes involved in the PPAR signaling pathway, antigen processing and presentation, and ferroptosis. SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were independent risk factors for a poor prognosis for patients with HCC and had diagnostic value. A risk model based on SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 expression showed that patients with HCC in the high-risk group had a worse prognosis. Consensus-clustering analysis (performed with K set to 2) distinguished two clusters (the cluster 1 and cluster 2 groups). Patients in cluster 1 survived significantly longer than those in cluster 2. The risk score correlated with the levels of T cells, cytotoxic lymphocytes, CD8(+) T cells, macrophages, memory B cells, follicular helper T cells, and other immune cells. The high risk based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 represented the poor prognosis for patients with HCC and significantly correlated with the levels of immune infiltrating cells in HCC.
format Online
Article
Text
id pubmed-9256406
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92564062022-07-06 A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC Liu, Xiang Zeng, Jian Li, Huanyu Li, Feng Jiang, Bin Zhao, Ming Liu, Zhuo Li, Ruineng Ma, Tiexiang J Oncol Research Article Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders to sorafenib were investigated using the HCC GSE109211 data set. Biological functions and mechanisms were studied using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. The expression levels of differential expressed target genes were identified in HCC tissues, using The Cancer Genome Atlas database, and their prognostic and diagnostic values were explored using survival and receiver operating characteristic curve analysis. A nomogram and risk model of sorafenib-response target genes enabled the evaluation of the prognosis of patients with HCC. The relationship between risk scores and levels of infiltrating immune cells was visualized via correlation analysis. We identified 1620 sorafenib-response target genes involved in the PPAR signaling pathway, antigen processing and presentation, and ferroptosis. SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were independent risk factors for a poor prognosis for patients with HCC and had diagnostic value. A risk model based on SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 expression showed that patients with HCC in the high-risk group had a worse prognosis. Consensus-clustering analysis (performed with K set to 2) distinguished two clusters (the cluster 1 and cluster 2 groups). Patients in cluster 1 survived significantly longer than those in cluster 2. The risk score correlated with the levels of T cells, cytotoxic lymphocytes, CD8(+) T cells, macrophages, memory B cells, follicular helper T cells, and other immune cells. The high risk based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 represented the poor prognosis for patients with HCC and significantly correlated with the levels of immune infiltrating cells in HCC. Hindawi 2022-06-28 /pmc/articles/PMC9256406/ /pubmed/35799605 http://dx.doi.org/10.1155/2022/7257738 Text en Copyright © 2022 Xiang Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Xiang
Zeng, Jian
Li, Huanyu
Li, Feng
Jiang, Bin
Zhao, Ming
Liu, Zhuo
Li, Ruineng
Ma, Tiexiang
A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title_full A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title_fullStr A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title_full_unstemmed A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title_short A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
title_sort risk model based on sorafenib-response target genes predicts the prognosis of patients with hcc
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/
https://www.ncbi.nlm.nih.gov/pubmed/35799605
http://dx.doi.org/10.1155/2022/7257738
work_keys_str_mv AT liuxiang ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT zengjian ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT lihuanyu ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT lifeng ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT jiangbin ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT zhaoming ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT liuzhuo ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT liruineng ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT matiexiang ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT liuxiang riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT zengjian riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT lihuanyu riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT lifeng riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT jiangbin riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT zhaoming riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT liuzhuo riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT liruineng riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc
AT matiexiang riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc